Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, will announce its second quarter and first half year 2016 results on Thursday, 25 August 2016. A presentation by Targovax’s senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET.
The presentation will also be webcast live and can be accessed through www.circio.com.
The presentation will take place at 10:00 CET at:
The results report and the presentation will be available at www.circio.com in the Investors section from 07:00 CET.
For further information, please contact:
Oystein Soug +47 90 65 65 25
Arming the patient’s immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.
ONCOS – 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system’s capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.
These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development. Targovax is listed on the Oslo Stock Exchange (Ticker: TRVX). For more information please visit www.circio.com.